Research graph
References from Safety of Biologic Therapy for Inflammatory Bowel Disease in Liver Transplant Recipients. Local targets link to admitted publications; unresolved targets remain external evidence.
Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments
10.1016/j.tips.2024.08.003 · 2024 · External reference
Pathophysiology of Crohn’s disease inflammation and recurrence
10.1186/s13062-020-00280-5 · 2020 · External reference
ECCO Guidelines on Therapeutics in Crohn′s Disease: Medical Treatment
10.1093/ecco-jcc/jjae091 · 2024 · External reference
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
10.1093/ecco-jcc/jjab178 · 2021 · External reference
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
10.1053/j.gastro.2021.08.032 · 2021 · External reference
10.1016/j.jhep.2022.05.011
10.1016/j.jhep.2022.05.011 · External reference
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
10.1002/hep.32771 · 2022 · External reference
Trends in liver transplantation for primary sclerosing cholangitis
10.1016/j.dld.2024.01.175 · 2024 · External reference
Understanding, predicting and achieving liver transplant tolerance: From bench to bedside
10.1038/s41575-020-0334-4 · 2020 · External reference
S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)
10.1055/a-2255-7246 · 2024 · External reference
Recurrence of primary Sclerosing Cholangitis after liver transplantation: Challenges, insights, and future directions
10.1016/j.dld.2026.03.016 · 2026 · External reference
Liver injury from tumor necrosis factor-α antagonists: Analysis of thirty-four cases
10.1016/j.cgh.2012.12.025 · 2013 · External reference
Safety of biologic treatments in solid organ transplant recipients: A systematic review
10.1016/j.semarthrit.2021.08.013 · 2021 · External reference
Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis
10.1093/ibd/izad108 · 2023 · External reference
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
10.1111/apt.70283 · 2025 · External reference
De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy
10.1159/000550240 · 2025 · External reference
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: A Nordic Multicentre Study
10.1080/00365521.2017.1421705 · 2018 · External reference
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study
10.1016/j.jhepr.2022.100599 · 2022 · External reference
Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis
10.1111/ctr.70436 · 2026 · External reference
Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients
10.3748/wjg.v24.i28.3171 · 2018 · External reference
Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis
10.1016/j.jhep.2019.05.006 · 2019 · External reference
Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant – A pilot study
10.1111/tri.13692 · 2020 · External reference
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
10.1002/hep.32771 · ExternalCitation · doi-reference
Liver injury from tumor necrosis factor-α antagonists: Analysis of thirty-four cases
10.1016/j.cgh.2012.12.025 · ExternalCitation · doi-reference
Trends in liver transplantation for primary sclerosing cholangitis
10.1016/j.dld.2024.01.175 · ExternalCitation · doi-reference
Recurrence of primary Sclerosing Cholangitis after liver transplantation: Challenges, insights, and future directions
10.1016/j.dld.2026.03.016 · ExternalCitation · doi-reference
Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis
10.1016/j.jhep.2019.05.006 · ExternalCitation · doi-reference
10.1016/j.jhep.2022.05.011
10.1016/j.jhep.2022.05.011 · ExternalCitation · doi-reference
Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study
10.1016/j.jhepr.2022.100599 · ExternalCitation · doi-reference
Safety of biologic treatments in solid organ transplant recipients: A systematic review
10.1016/j.semarthrit.2021.08.013 · ExternalCitation · doi-reference
Ulcerative colitis: Clinical biomarkers, therapeutic targets, and emerging treatments
10.1016/j.tips.2024.08.003 · ExternalCitation · doi-reference
Understanding, predicting and achieving liver transplant tolerance: From bench to bedside
10.1038/s41575-020-0334-4 · ExternalCitation · doi-reference
Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
10.1053/j.gastro.2021.08.032 · ExternalCitation · doi-reference
S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)
10.1055/a-2255-7246 · ExternalCitation · doi-reference
Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: A Nordic Multicentre Study
10.1080/00365521.2017.1421705 · ExternalCitation · doi-reference
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
10.1093/ecco-jcc/jjab178 · ExternalCitation · doi-reference
ECCO Guidelines on Therapeutics in Crohn′s Disease: Medical Treatment
10.1093/ecco-jcc/jjae091 · ExternalCitation · doi-reference
Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis
10.1093/ibd/izad108 · ExternalCitation · doi-reference
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
10.1111/apt.70283 · ExternalCitation · doi-reference
Risk Factors for Primary Sclerosing Cholangitis Recurrence Following Liver Transplantation: A Multicenter Retrospective Analysis
10.1111/ctr.70436 · ExternalCitation · doi-reference
Recurrence of primary sclerosing cholangitis after liver transplantation is associated with specific changes in the gut microbiome pretransplant – A pilot study
10.1111/tri.13692 · ExternalCitation · doi-reference
De novo Inflammatory Bowel Disease following Liver and Heart Transplantation: A Case Series Exploring the Role of IL-23 Pathway-Targeted Therapy
10.1159/000550240 · ExternalCitation · doi-reference
Pathophysiology of Crohn’s disease inflammation and recurrence
10.1186/s13062-020-00280-5 · ExternalCitation · doi-reference
Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients
10.3748/wjg.v24.i28.3171 · ExternalCitation · doi-reference
